EA034214B1 - Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты - Google Patents

Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты Download PDF

Info

Publication number: EA034214B1
Authority: EA; Eurasian Patent Office
Prior art keywords: antibody; tfpi; monoclonal antibody; fab; epitope
Prior art date: 2011-04-01

Application number

EA201301107A

Other languages

English (en)

Russian (ru)

Other versions

EA201301107A1 (ru

Inventor

Чжучжи Ван

Джон Мёрфи

Тобиас Марквардт

Дитер Мосмайер

Original Assignee

Байер Хелфкеа Ллк

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2012-03-30

Publication date

2020-01-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA034214(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-03-30 Application filed by Байер Хелфкеа Ллк filed Critical Байер Хелфкеа Ллк

2014-11-28 Publication of EA201301107A1 publication Critical patent/EA201301107A1/ru

2020-01-17 Publication of EA034214B1 publication Critical patent/EA034214B1/ru

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EA201301107A 2011-04-01 2012-03-30 Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты EA034214B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161471101P	2011-04-01	2011-04-01
PCT/US2012/031538 WO2012135671A2 (en)	2011-04-01	2012-03-30	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (2)

Publication Number	Publication Date
EA201301107A1 EA201301107A1 (ru)	2014-11-28
EA034214B1 true EA034214B1 (ru)	2020-01-17

Family

ID=46932389

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EA201301107A EA034214B1 (ru)	2011-04-01	2012-03-30	Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты
EA201991704A EA201991704A3 (ru)	2011-04-01	2012-03-30	Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EA201991704A EA201991704A3 (ru)	2011-04-01	2012-03-30	Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)

Country Status (37)

Country	Link
US (5)	US20140294832A1 (2)
EP (1)	EP2694544B1 (2)
JP (4)	JP6170903B2 (2)
KR (2)	KR20190079698A (2)
CN (2)	CN103797030B (2)
AU (3)	AU2012236296A1 (2)
BR (1)	BR112013025376A2 (2)
CA (2)	CA2831907C (2)
CL (1)	CL2013002811A1 (2)
CO (1)	CO6890074A2 (2)
CR (1)	CR20130499A (2)
CU (1)	CU20130128A7 (2)
CY (1)	CY1121538T1 (2)
DK (1)	DK2694544T3 (2)
DO (1)	DOP2013000218A (2)
EA (2)	EA034214B1 (2)
EC (1)	ECSP13012913A (2)
ES (1)	ES2722824T3 (2)
GT (1)	GT201300229A (2)
HK (1)	HK1243426A1 (2)
HR (1)	HRP20190467T1 (2)
HU (1)	HUE042706T2 (2)
IL (4)	IL228633B (2)
LT (1)	LT2694544T (2)
MX (1)	MX2013011218A (2)
MY (2)	MY190951A (2)
PE (1)	PE20141149A1 (2)
PH (4)	PH12013502039B1 (2)
PL (1)	PL2694544T3 (2)
PT (1)	PT2694544T (2)
RS (1)	RS58633B1 (2)
SG (2)	SG193594A1 (2)
SI (1)	SI2694544T1 (2)
TR (1)	TR201905101T4 (2)
UA (1)	UA113623C2 (2)
WO (1)	WO2012135671A2 (2)
ZA (1)	ZA201308169B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101792032B1 (ko)	2008-12-19	2017-11-02	백스터 인터내셔널 인코포레이티드	Ｔｆｐｉ 억제제 및 사용 방법
WO2010072691A1 (en) †	2008-12-22	2010-07-01	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor
PT3345615T (pt)	2010-03-01	2020-01-17	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
DK2547355T3 (en)	2010-03-19	2017-03-20	Baxalta GmbH	TFPI INHIBITORS AND METHODS OF USE
PL2694544T3 (pl) *	2011-04-01	2019-07-31	Bayer Healthcare Llc	Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
BR112014022435B1 (pt)	2012-03-21	2023-02-14	Takeda Pharmaceutical Company Limited	Inibidores de tfpi e métodos de uso
US9975962B2 (en)	2012-03-30	2018-05-22	Bayer Healthcare Llc	Thrombin/plasmin-regulated antibodies that bind TFPI
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US9896513B2 (en) *	2013-03-15	2018-02-20	Novo Nordisk A/S	Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
EP2970497B1 (en)	2013-03-15	2017-10-25	Bayer HealthCare LLC	Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
EP3022228B1 (en)	2013-07-19	2019-02-27	Novo Nordisk A/S	Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
JP6783754B2 (ja) *	2014-09-17	2020-11-11	ノヴォノルディスクアー／エス	組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
MY178445A (en) *	2015-02-25	2020-10-13	Mogam Inst Biomedical Res	Novel antibody binding to tfpi and composition comprising the same
KR102438650B1 (ko) *	2015-08-19	2022-08-31	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도
JP7444059B2 (ja) *	2018-07-25	2024-03-06	ソニーグループ株式会社	血液凝固系解析装置
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010017196A2 (en) *	2008-08-04	2010-02-11	Bayer Healthcare Llc	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2010072691A1 (en) *	2008-12-22	2010-07-01	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06153985A (ja) *	1992-11-16	1994-06-03	Teijin Ltd	モノクローナル抗体
PT3345615T (pt) *	2010-03-01	2020-01-17	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
PL2694544T3 (pl) *	2011-04-01	2019-07-31	Bayer Healthcare Llc	Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
US8613919B1 (en) *	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations

2012
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039B1/en unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
2019
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010017196A2 (en) *	2008-08-04	2010-02-11	Bayer Healthcare Llc	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2010072691A1 (en) *	2008-12-22	2010-07-01	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UniProt submission P10646, TFPI1 HUMAN, 01 July 1989 [online]. [Retrieved on 2012-06-11]. Retrieved from the internet <URL: http://www.uniprot.org/uniprot/P10646.txt?version=151> *

Also Published As

Publication number	Publication date
CN103797030B (zh)	2017-05-31
LT2694544T (lt)	2019-04-25
IL228633A0 (en)	2013-12-31
RS58633B1 (sr)	2019-05-31
CL2013002811A1 (es)	2014-02-28
KR20140019428A (ko)	2014-02-14
EA201991704A2 (ru)	2020-03-31
PH12019500441A1 (en)	2020-10-12
MY165499A (en)	2018-03-27
JP2021019619A (ja)	2021-02-18
PH12019500439A1 (en)	2020-10-12
HUE042706T2 (hu)	2019-07-29
IL283829A (en)	2021-07-29
CA3068997A1 (en)	2012-10-04
US20220041752A1 (en)	2022-02-10
PL2694544T3 (pl)	2019-07-31
CR20130499A (es)	2013-10-24
CA2831907A1 (en)	2012-10-04
ZA201308169B (en)	2016-03-30
AU2017203105A1 (en)	2017-06-01
JP2017113019A (ja)	2017-06-29
HK1243426A1 (zh)	2018-07-13
IL257145A (en)	2018-03-29
CA2831907C (en)	2020-03-24
CO6890074A2 (es)	2014-03-10
MX2013011218A (es)	2013-10-17
TR201905101T4 (tr)	2019-05-21
EA201991704A3 (ru)	2020-06-30
WO2012135671A2 (en)	2012-10-04
BR112013025376A2 (pt)	2017-07-25
IL274686B (en)	2021-09-30
EP2694544B1 (en)	2019-01-23
JP6363747B2 (ja)	2018-07-25
EP2694544A4 (en)	2015-03-25
CY1121538T1 (el)	2020-05-29
PH12013502039A1 (en)	2013-12-16
US20140294832A1 (en)	2014-10-02
US20170107298A1 (en)	2017-04-20
GT201300229A (es)	2014-11-13
ECSP13012913A (es)	2014-02-28
IL228633B (en)	2018-03-29
AU2019201814A1 (en)	2019-04-04
ES2722824T3 (es)	2019-08-19
SI2694544T1 (sl)	2019-06-28
JP2018172411A (ja)	2018-11-08
EP2694544A2 (en)	2014-02-12
IL274686A (en)	2020-06-30
DOP2013000218A (es)	2013-11-15
KR20190079698A (ko)	2019-07-05
JP2014511685A (ja)	2014-05-19
WO2012135671A3 (en)	2012-12-13
KR101995302B1 (ko)	2019-07-02
US20180194857A1 (en)	2018-07-12
US20190194353A1 (en)	2019-06-27
AU2012236296A1 (en)	2013-10-24
SG10201602606UA (en)	2016-04-28
PH12013502039B1 (en)	2013-12-16
MY190951A (en)	2022-05-24
PH12019500440A1 (en)	2020-10-12
EA201301107A1 (ru)	2014-11-28
PE20141149A1 (es)	2014-08-28
UA113623C2 (uk)	2017-02-27
SG193594A1 (en)	2013-10-30
HRP20190467T1 (hr)	2019-05-03
CN107090046A (zh)	2017-08-25
NZ615969A (en)	2016-01-29
PT2694544T (pt)	2019-04-02
CN103797030A (zh)	2014-05-14
DK2694544T3 (en)	2019-04-15
CU20130128A7 (es)	2014-03-26
JP6170903B2 (ja)	2017-07-26

Legal Events

Date	Code	Title	Description
2020-11-30	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM RU

Publication	Publication Date	Title
US20220041752A1 (en)	2022-02-10	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
KR101974980B1 (ko)	2019-05-07	조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
AU2016269554B2 (en)	2018-12-20	Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2013202745B2 (en)	2017-01-05	Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HK40018254A (en)	2020-09-30	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1197829A (en)	2015-02-18	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1197829B (en)	2018-04-06	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ615969B2 (en)	2016-05-03	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)